What’s wrong in govt consulting industry for policies?

  Last week the famous whistle blower in Ranbaxy data fudging case wrote in Scroll that the Indian drug regulator is “inept” in regulating biosimilars, a new class of drugs that have come to dominate the market and will increasingly do so for the next decade.   Dinesh Thakur certainly has a point but it […]